Cortendo Appoints Robert Lutz As Chief Business Officer
GÖTEBORG, Sweden & RADNOR, Penn.--(BUSINESS WIRE)--Regulatory News: Cortendo AB [ticker: CORT on NOTC-A], a global biopharmaceutical company focused on orphan endocrine disorders, announced the appointment of Robert Lutz as Chief Business Officer.
Lutz brings deep experience in strategy, forecasting and commercialization from the specialty pharmaceutical industry, including more than a decade at Shire Pharmaceuticals. Lutz will lead the implementation of Cortendo's commercial strategy for COR-003 (levdexketoconazole), as well as business development and other corporate functions.